Phase I/II trial of Lenalidomide plus Bortezomib combined with Dexamethasone in patients in 1st relapse or primary refractory after first line therapy for Multiple Myeloma

Trial Profile

Phase I/II trial of Lenalidomide plus Bortezomib combined with Dexamethasone in patients in 1st relapse or primary refractory after first line therapy for Multiple Myeloma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Feb 2017

At a glance

  • Drugs Bortezomib (Primary) ; Lenalidomide (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms HOVON 86 MM
  • Most Recent Events

    • 21 Feb 2017 This study has been completed in Belgium.
    • 24 Mar 2012 Additional location (Belgium) added as reported by European Clinical Trials Database record.
    • 24 Mar 2012 Planned number of patients changed from 72 to 84 as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top